advertisement
Abstract #104434 Published in IGR 23-2
Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
Pahljina C; Sarny S; Hoeflechner L; Falb T; Schliessleder G; Lindner M; Lindner M; Ivastinovic D; Mansouri K; Lindner EJournal of clinical medicine 2022; 11:
Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)-questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation ("hard to see in daylight", 75.0 ± 31.1 vs. 57.7 ± 39.1, = 0.035; "hard to see in dark places", 81.1 ± 28.7 vs. 54.9 ± 41.2, = 0.002; and "halos around lights", 88.3 ± 25.9 vs. 68.8 ± 38.6, = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed.
Department of Ophthalmology, Medical University Graz, 8036 Graz, Austria.
Full article